CTKB Stock Analysis: Cytek Biosciences | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 593m USD | 12M Return: 29.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.76M
Qual. Beats: -1
Rev. Trend: 72.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cytek Biosciences, Inc. (NASDAQ: CTKB) is a cell analysis solutions company that develops and sells flow cytometry instruments, reagents, and software used in biomedical research and clinical applications. Its product portfolio includes the Cytek Aurora, Northern Lights, and Aurora Evo systems, the Cytek Aurora CS system for cellular complexity analysis, Amnis imaging flow cytometers, and Guava-branded Muse and easyCyte cell analyzers, along with the Cytek Orion reagent cocktail preparation system and SpectroFlo analysis software. The company also markets cFluor reagent kits (fluorochrome-conjugated antibodies) designed to run on its instruments, giving it a mix of capital equipment sales and recurring consumables revenue.
The company sells its instruments and reagents to pharmaceutical and biopharma companies, academic research centers, and contract research organizations, using a direct sales force across North America, Europe, China, and the Asia-Pacific region, supplemented by distributors in Europe, Latin America, and the Middle East. Flow cytometry is a core technology in immunology, oncology, and drug discovery research, supporting demand from both academic and commercial life sciences customers. The company was founded in 1992, is headquartered in Fremont, California, was formerly known as Cytoville, Inc. before rebranding in August 2015, and completed its IPO in July 2021.
- Reagent and kit sales expand as instrument installed base grows
- Biotech research funding pressures academic and pharma customer budgets
- Competition from BD and Beckman Coulter pressures flow cytometry market share
| Net Income: -74.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -6.46 > 1.0 |
| NWC/Revenue: 146.1% < 20% (prev 158.7%; Δ -12.61% < -1%) |
| CFO/TA -0.02 > 3% & CFO -7.30m > Net Income -74.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.7m) vs 12m ago 0.29% < -2% |
| Gross Margin: 51.70% > 18% (prev 54.94%; Δ -3.24% > 0.5%) |
| Asset Turnover: 43.83% > 50% (prev 40.83%; Δ 3.00% > 0%) |
| Interest Coverage Ratio: -17.97 > 6 (EBIT TTM -34.1m / Interest Expense TTM 1.90m) |
| A: 0.66 (Total Current Assets 379.3m - Total Current Liabilities 80.9m) / Total Assets 449.1m |
| B: -0.27 (Retained Earnings -120.6m / Total Assets 449.1m) |
| C: -0.07 (EBIT TTM -34.1m / Avg Total Assets 465.9m) |
| D: 2.70 (Book Value of Equity 327.6m / Total Liabilities 121.5m) |
| Altman-Z'' = 5.82 = AAA |
| DSRI: 0.99 (Receivables 56.5m/55.2m, Revenue 204.2m/197.1m) |
| GMI: 1.06 (GM 54.94% / 51.70%) |
| AQI: 0.56 (AQ_t 0.09 / AQ_t-1 0.15) |
| SGI: 1.04 (Revenue 204.2m / 197.1m) |
| TATA: -0.15 (NI -74.0m - CFO -7.30m) / TA 449.1m) |
| Beneish M = -3.23 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 4.62 with a total of 788,320 shares traded. Over the past week, the price has changed by +0.65%, over one month by +14.07%, over three months by +1.99% and over the past year by +29.78%.
Current recommended Stop Loss: 4.30 (which is 6.9% or 1.4 ATR below the current price).
Cytek Biosciences has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold CTKB.
- StrongBuy: 1
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 5.7 | 23.2% |
P/E Forward = 370.3704
P/S = 2.9033
P/B = 1.8092
Revenue TTM = 204.2m USD
EBIT TTM = -34.1m USD
EBITDA TTM = -22.1m USD
Long Term Debt = 386k USD (from longTermDebt, last quarter)
Short Term Debt = 15.9m USD (from shortTermDebt, last quarter)
Debt = 52.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 16.4m
Net Debt = -209.5m USD (calculated: Debt 52.7m - CCE 262.2m)
Enterprise Value = 383.3m USD (592.8m + Debt 52.7m - CCE 262.2m)
Interest Coverage Ratio = -17.97 (Ebit TTM -34.1m / Interest Expense TTM 1.90m)
EV/FCF = -30.18x (Enterprise Value 383.3m / FCF TTM -12.7m)
FCF Yield = -3.31% (FCF TTM -12.7m / Enterprise Value 383.3m)
FCF Margin = -6.22% (FCF TTM -12.7m / Revenue TTM 204.2m)
Net Margin = -36.25% (Net Income TTM -74.0m / Revenue TTM 204.2m)
Gross Margin = 51.70% ((Revenue TTM 204.2m - Cost of Revenue TTM 98.6m) / Revenue TTM)
Gross Margin QoQ = 48.16% (prev 52.92%)
Tobins Q-Ratio = 0.85 (Enterprise Value 383.3m / Total Assets 449.1m)
Interest Expense / Debt = 3.60% (Interest Expense 1.90m / Debt 52.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -26.9m (EBIT -34.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.69 (Total Current Assets 379.3m / Total Current Liabilities 80.9m)
Debt / Equity = 0.16 (Debt 52.7m / totalStockholderEquity, last quarter 327.6m)
Debt / EBITDA = 9.46 (negative EBITDA) (Net Debt -209.5m / EBITDA -22.1m)
Debt / FCF = 16.50 (negative FCF - burning cash) (Net Debt -209.5m / FCF TTM -12.7m)
Total Stockholder Equity = 356.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.89% (Net Income -74.0m / Total Assets 449.1m)
RoE = -20.77% (Net Income TTM -74.0m / Total Stockholder Equity 356.4m)
RoCE = -9.54% (EBIT -34.1m / Capital Employed (Equity 356.4m + L.T.Debt 386k))
RoIC = -7.20% (negative operating profit) (NOPAT -26.9m / Invested Capital 373.8m)
WACC = 9.93% (E(592.8m)/V(645.5m) * Re(10.56%) + D(52.7m)/V(645.5m) * Rd(3.60%) * (1-Tc(0.21)))
Discount Rate = 10.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -0.69%
[DCF] Fair Price = unknown (Cash Flow -12.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.89 | # QB: -1
Revenue Correlation: 72.48 | Revenue CAGR: 3.59% | SUE: -0.07 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.01 | Chg30d=+75.00% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.01 | Chg30d=N/A | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.04 | Chg30d=+52.94% | Revisions=+0% | GrowthEPS=+87.2% | GrowthRev=+3.6%
EPS next Year (2027-12-31): EPS=0.19 | Chg30d=+322.22% | Revisions=-25% | GrowthEPS=+575.0% | GrowthRev=+6.6%